Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 1999

View Archived Issues

ImmGenics and Genzyme enter collaboration agreement to use SLAM technology

Gene Logic and UCB Research enter allergy and asthma gene expression agreement

Soluble Tat peptide analogues, HIV replication inhibitors, available for licensing from NIH

Icos highlights clinical results from product development program

Takeda to collaborate in the development of Dainippon's candidate antidiabetic

Genzyme Molecular Oncology licenses antisense cancer rights to Hybridon

Zambon and Sheffield initiate MSI albuterol trial for treatment of pediatric asthma

Isis and RPR establish collaboration for antisense target validation

Yale study will evaluate memantine's ability to prevent vision loss in glaucoma patients

Cytokine inhibitors from Ortho-McNeil and methods of treating rheumatoid arthritis, etc.

New muscarinic antagonists developed at Roche

Shionogi's new immunosuppressant/antiallergic compounds

Promising anti-HIV drug candidate strongly inhibits T-tropic and T/M-tropic infections in SCID mice

In vivo efficacy and CNS toxicity of T-3811ME described at major congress

Lilly's PTH analogue LY-333334 featured at this week's ASBMR meeting

BMS seeks FDA approval for novel oral antidiabetic drug

Novel semisynthetic pleuromutilins with potential as topical antibacterial agents

Scotia seeks FDA approval for Foscan PDT

Novo Nordisk takes a different tack in search of greater strength

Profile of new small-molecule CCR5 antagonist from Takeda detailed further at ICAAC

Geranylgeranyltransferase inhibition as a mechanism for specifically inhibiting bone resorption

Medco initiates phase II trial of MRE-0470

Compound from Streptomyces inhibits bone resorption, induces apoptosis in osteoclasts in vitro

Glaxo Wellcome launches lamivudine in China for treatment of chronic HBV

ICAAC news: anti-HIV-1 activity and enzyme/drug interactions of (+)-calanolide A

British Biotech moves novel rheumatoid arthritis treatment into development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...